Samsung Biologics Co., Ltd.
207940 · Korea Exchange (KRX) — KOSPI · Healthcare — Biopharmaceutical Manufacturing (CDMO)
About the company
Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) by biopharmaceutical production capacity, producing biologics drugs for pharmaceutical clients across four large-scale plants in Incheon, South Korea. The company is a Samsung Group affiliate and is constructing a fifth plant to further expand capacity. It serves leading global pharmaceutical companies and benefits from growing biologic drug outsourcing trends.
| Exchange | Korea Exchange (KRX) — KOSPI |
| Ticker | 207940 |
| Sector | Healthcare — Biopharmaceutical Manufacturing (CDMO) |
| Indicative market cap USD | $54.00B |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
On its home market (Korea Exchange (KRX) — KOSPI), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange — official exchange listing
Availability information only — not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in South Korea
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only — not investment advice. Verify with the exchange, the company's filings and your broker.